The study evaluated the effectiveness of vaginal laser therapy (VL) and hyaluronic acid suppositories (HAS) in women with urogenital atrophy after having breast cancer (BC) treatment. The data found that both VA therapy and HAS were equally effective in treating urogenital atrophy in these patients.

The study compared the effectiveness and safety of pertuzumab (Perjeta) and trastuzumab (Herceptin) combined therapy with trastuzumab alone in patients with HER2-positive (HER2+) advanced breast cancer (BC). The study found that the combined therapy was more effective and well tolerated compared to single therapy in these patients. 

This study evaluated the impact of immune checkpoint inhibitors (ICIs) on COVID-19 outcomes in patients with cancer. The data showed that the use of ICI treatment before COVID-19 infection does not affect the disease severity or survival outcomes. This study supports the continued use of ICIs in cancer patients during the pandemic.

The study investigated the effects of vitamin D (Vit D) supplementation in patients with early breast cancer receiving doxorubicin (DOX; Adriamycin)-based chemotherapy. The results showed that patients taking DOX plus Vit D had improved heart-related blood markers.

This study evaluated the effects of physical therapies on improvement in psychosomatic symptoms and quality of life (QoL) in patients with breast cancer (BC) treated with aromatase inhibitors (AIs). The data showed that acupuncture can significantly reduce pain intensity and exercise training might improve QoL in these patients. 

This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness.

This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations.

This study investigated the optimal doses of hypofractionated stereotactic radiation therapy (HSRT) for patients with brain metastases (BM). The data showed that a HSRT dose of 30 Gy or higher delivered in 5 daily fractions was safe and effective in these patients.

This study evaluated the effectiveness and safety of different anti-HER2 therapies in combination with chemotherapy for the treatment of patients with metastatic HER2-positive breast cancer (BC). The data showed that THP (taxanes + trastuzumab + pertuzumab) was the best first-line treatment, while Trastuzumab emtansine (T-DM1; Kadcycla) and XHTuC (capecitabine + trastuzumab + tucatinib) were the best second-line treatments for metastatic HER2-positive BC.

The authors evaluated the efficacy and safety of pyrotinib (Irene), for the treatment of HER2- positive metastatic breast cancer (MBC) in a real-world setting. The authors observed that pyrotinib was effective and well tolerated by patients.